Proactive Investors - Run By Investors For Investors

Synairgen reports strong interest in new fibrosis treatment ahead of Phase I trial

PXS-5382A, an inhibitor that aids breathing in patients by targeting the LOXL2 enzyme, is being developed with Australian firm Pharmaxis.
picture of lungs
Synairgen's new drug might potentially treat a number of indications

Synairgen PLC (LON:SNG) has reported significant industry interest in its new idiopathic pulmonary fibrosis treatment ahead of the start of clinical trials.

Richard Marsden, Synairgen’s chief executive, said: "Based on PXS-5382A's potential across a number of disease areas and the promising data seen to date, we have received significant interest from companies looking to license the programme for multiple indications.”

READ: Synairgen pleased with the progress made with the LOXL2 programme

The respiratory drug developer confirmed in a statement that it is to start a Phase I (safety) trial of the new treatment for sufferers of idiopathic pulmonary fibrosis in the fourth quarter of 2017 after completing pre-clinical studies.

PXS-5382A, an inhibitor that aids breathing in patients by targeting the LOXL2 enzyme, is being developed with Australian firm Pharmaxis.

Results from the Phase I trial are scheduled for the middle of 2018, after which the aim is to find a partner to license the drug due to size of the potential market and number of indications it could address.

WATCH: Synairgen's chief hails exciting IPF data from LOXL2 inhibitor programme

Though IPF is the initial target, LOXL2 is believed to be an important factor in other fibrotic diseases such as NASH, cardiac fibrosis and kidney fibrosis, all of which are areas of high unmet need currently.

“PXS-5382A is a very valuable candidate with potential applications in a number of fibrotic conditions with very substantial market opportunities,” said Marsden. 

"The effect of this novel inhibitor across different model types is very exciting, with the latest supporting data suggesting that PXS-5382A can significantly reduce lung fibrosis and therefore has the potential to improve lung function in severely ill patients.”

View full SNG profile View Profile

Synairgen plc Timeline

Big Picture
March 15 2018

Related Articles

March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc
December 18 2017
VAL201 is a treatment for metastatic prostate cancer and other solid tumours
cancer cell
January 31 2018
The highlights included successful US and European ovarian cancer studies that underlined the potential of the company’s Parsortix liquid biopsy system

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use